{"id":356,"date":"2019-03-03T00:33:14","date_gmt":"2019-03-03T08:33:14","guid":{"rendered":"http:\/\/kinaseinhibitorlibrary.com\/?p=356"},"modified":"2022-01-13T16:32:33","modified_gmt":"2022-01-13T09:32:33","slug":"copd-pathology-affected-results-present-studysubjects-cop","status":"publish","type":"post","link":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/2019\/03\/03\/copd-pathology-affected-results-present-studysubjects-cop\/","title":{"rendered":"COPD pathology is unlikely to have affected the results of the present study, as no subjects have a known COP"},"content":{"rendered":"

However, we acknowledge the limitation that the different effects of “light” and “heavy” smoking on the association between FENO and UNC2881<\/a> bronchial responsiveness could not be fully confirmed when performing a statistical interaction test. We were able to confirm in this large population sample that the previous reported association between FENO and increased bronchial responsiveness in adults was significant only in atopic subjects. Atopy-related increase in FENO is due probably to the eosinophilic subclinical inflammation in the airways, as the link between FENO and eosinophilic inflammation is well known. The mechanism behind increased bronchial responsiveness in atopic subjects is most probably due to a combination of subclinical eosinophilic inflammation and remodeling changes described in the airways of atopic subjects. A Th2-driven allergic response via IL-4-IL-13 cytokines could well result in both increased NO and increased bronchial responsiveness. The present study fills a gap regarding the effect of smoking on the association between bronchial responsiveness and FENO and it also made it possible to analyze the interactions of atopy and smoking on the association between bronchial responsiveness and FENO. The only group where we did find an association of increased FENO values with increased bronchial responsiveness was the group of non-smoking atopic individuals. We found similar levels of FENO among the non-atopic non-smoking subjects and atopic smoking subjects due to the fact that FENO is affected both by smoking and atopy. The main weakness of the present study resides in the different methods to measure FENO in the participating centers. We used quartiles of FENO instead of absolute values of FENO and no heterogeneity between centers was found regarding the interaction of smoking and atopy, respectively, with the relationship between FENO and bronchial responsiveness. An indirect validation of this method of using FENO quartiles in the present material is obtained by confirming the previous results on the relationship between FENO and bronchial responsiveness. The fact that in one center FENO was measured by higher flow-rate, which theoretically can sample to a slightly higher extent the peripheral airways, appears to be scarcely influent in this study, as atopy does not affect alveolar NO and current smoking leads only to minor Citiolone<\/a> decrease of alveolar in comparison with bronchial contribution to exhaled NO. Moreover, the main results could be confirmed in a subanalysis performed only in Gothenburg and Uppsala. In our population sample atopic subjects are underrepresented in the current smokers group, probably because the subjects with atopy and bronchial hyperresponsiveness might be less prone to start smoking. However this does not appear to confound our results, since the proportion of atopics increase with each FENO quartile among the smokers without any corresponding increase in BR levels.<\/p>\n","protected":false},"excerpt":{"rendered":"

However, we acknowledge the limitation that the different effects of “light” and “heavy” smoking on the association between FENO and UNC2881 bronchial responsiveness could not be fully confirmed when performing a statistical interaction test. We were able to confirm in this large population sample that the previous reported association between FENO and increased bronchial responsiveness … Continue reading COPD pathology is unlikely to have affected the results of the present study, as no subjects have a known COP<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/356"}],"collection":[{"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/comments?post=356"}],"version-history":[{"count":1,"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/356\/revisions"}],"predecessor-version":[{"id":357,"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/posts\/356\/revisions\/357"}],"wp:attachment":[{"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/media?parent=356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/categories?post=356"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/kinaseinhibitorlibrary.com\/index.php\/wp-json\/wp\/v2\/tags?post=356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}